Medical News

[ Moberg Derma AB: Moberg Derma Obtains Approval For Treatment For Atopic Eczema And Dry Skin ]

Moberg Derma AB: Moberg Derma Obtains Approval For Treatment For Atopic Eczema And Dry Skin

Moberg Derma AB (publ.) (STO:MOB) today announced that CE mark has been granted for Kaprolac Skin Repair & Hydration, a product designed to treat atopic eczema and dry skin. This CE mark provides authorization to market and sell the product in the EU/EEA. Kaprolac Skin Repair & Hydration is a new, steroid-free treatment option for eczema and dry skin, such as atopic eczema. Treatment of eczema is a field which has been dominated by older products, with few new launches over the past few years, and Kaprolac Skin Repair & Hydration has properties which meet significant needs in the treatment of atopic eczema. "We are now looking forward to working together with partners and distributors to make this product available to patients. The benign safety profile makes this Kaprolac product an interesting alternative for patients who are affected by recurrent and protracted problems with eczema.

Study Of Infections Associated With Eczema

The National Institute of Allergy and Infections Disease has awarded a five-year $31 million contract to National Jewish Health, which is leading a consortium of academic medical centers seeking to better understand skin infections associated with atopic dermatitis. The researchers will focus on antibiotic-resistant staphylococcus aureus ( MRSA ) infections and widespread viral infections of the skin, both of which are more prevalent among atopic dermatitis patients. "MRSA is a significant public health threat that needs to be contained, " said principal investigator Donald Leung, MD, PhD, Professor of Allergy and Clinical Immunology at National Jewish Health. "We want to find out why these patients are susceptible to staph infections, particularly MRSA, and learn how we can prevent them from developing and spreading to others.

Cellceutix Corporation Selects Destum Partners To Partner Psoriasis Compound

Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that it has selected Destum Partners to assist in finding a development partner for its psoriasis compound, KM-133. Cellceutix management has carefully evaluated which direction to take in the development of KM-133 and has concluded that this is the best way to create shareholder value. In a human xenograft animal model of psoriasis, KM-133 reduced psoriasis significantly more than controls. Psoriasis did not recur with KM-133 during the entire 180 day course of the experiment, whereas psoriasis reoccurred in the groups treated with methotrexate, a drug commonly used for the treatment of severe psoriasis, after an average of 61 days. The effectiveness demonstrated by KM-133 in these studies, if confirmed in human trials, would position the compound in a very large market.

Obesity In Early Adulthood Associated With Increased Risk Of Psoriatic Arthritis

Among persons with psoriasis, those who reported being obese at age 18 had an increased risk of developing psoriatic arthritis, according to a report in the July 19 issue of Archives of Dermatology, one of the JAMA/Archives journals. Psoriatic arthritis is a specific type of arthritis that develops in the joints of some patients who have psoriasis. According to background information in the article, " obesity has emerged as a significant risk factor for psoriasis, " and "psoriatic arthritis affects 6 percent to 42 percent of people with psoriasis." Additionally, "psoriatic arthritis shares some clinical features with rheumatoid arthritis, both leading to joint destruction and significant morbidity." Razieh Soltani-Arabshahi, M.D., of the University of Utah School of Medicine, Salt Lake City, and colleagues studied a volunteer sample of patients with dermatologist-diagnosed psoriasis enrolled in the Utah Psoriasis Initiative from November 2002 to October 2008.

Paracetamol Acetaminophen, Tylenol Doubles Risk Of Asthma And Eczema In Adolescents

Acetaminophen, more commonly known as Tylenol in the USA and paracetamol in Europe has been linked to the development of asthma and eczema among adolescents. A new study reveals that even monthly use of acetaminophen can more than double the risk, while yearly use may increase the risk by 50%. You can read about this new study in the upcoming issue of the American Journal of Respiratory and Critical Care Medicine. Richard Beasley, M.D., professor of medicine, at the Medical Research Institute of New Zealand on behalf of the International Study of Asthma and Allergies in Childhood (ISAAC), said: This study has identified that the reported use of acetaminophen in 13- and 14 year old adolescent children was associated with an exposure-dependent increased risk of asthma symptoms. Part of the ISAAC program included two written questionnaires, as well as a video questionnaire.

Fast: [10]

Medical News © Nanda
Designer Damodar